



March 20, 2025

**BSE Limited**  
Floor 25, P. J. Towers  
Dalal Street,  
**Mumbai - 400 001**

**The National Stock Exchange of India Limited**  
Exchange Plaza  
Bandra Kurla Complex  
Bandra (E)  
**Mumbai - 400 051**

**Scrip Code: 530019**

**Symbol: JUBLPHARMA**

**Re.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sirs,

In continuation to our disclosure letters dated August 16, 2024, October 4, 2024, and January 29, 2025, we are pleased to inform that Jubilant Biosys Innovative Research Services Pte Limited, Singapore ("JBIRSPL"), a subsidiary of Jubilant Biosys Limited, a wholly owned subsidiary of the Company, has executed Shareholders' Agreement and other transition agreements with Pierre Fabre SA, and its affiliate entities ("PF"), and subscribed to 80% equity capital in JASMIN, a company incorporated by PF in France, as a Société par Actions Simplifiée (SAS), with remaining 20% equity capital retained by PF. Simultaneously, the acquisition by JASMIN of PF's R&D Centre (including R&D Site and R&D activities) at Saint Julien, France stands successfully closed. On closure of transaction, name of JASMIN has been changed to '**Jubilant Biosys France**' which is now a subsidiary of JBIRSPL.

The date and time of occurrence of event is 11:54 pm (IST) on Wednesday, March 19, 2025.

We request you to take the same on record.

Thanking you,

Yours faithfully,  
For Jubilant Pharmova Limited

Naresh Kapoor  
Company Secretary

A Jubilant Bhartia Company

OUR VALUES



**Jubilant Pharmova Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
[www.jubilantpharmova.com](http://www.jubilantpharmova.com)

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223  
UP, India  
CIN : L24116UP1978PLC004624